Application 050748

Type
NDA
Sponsor
KING PHARMS

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001SYNERCIDDALFOPRISTIN; QUINUPRISTININJECTABLE;INTRAVENOUS350MG/VIAL;150MG/VIALYesYes
002SYNERCIDDALFOPRISTIN; QUINUPRISTININJECTABLE;INTRAVENOUS420MG/VIAL;180MG/VIALNoNo

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N050748-001SYNERCIDDALFOPRISTIN; QUINUPRISTIN350MG/VIAL;150MG/VIALINJECTABLE / INTRAVENOUSRLD1999-09-21
N050748-002SYNERCIDDALFOPRISTIN; QUINUPRISTIN420MG/VIAL;180MG/VIALINJECTABLE / INTRAVENOUS2000-08-24

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 3 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N050748-001SYNERCID350MG/VIAL;150MG/VIALINJECTABLE / INTRAVENOUSRLD, RS1999-09-213a93d1ddd44b…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N050748-002SYNERCID420MG/VIAL;180MG/VIALINJECTABLE / INTRAVENOUS2000-08-243a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N050748-001SYNERCID350MG/VIAL;150MG/VIALINJECTABLE / INTRAVENOUSRLD, RS1999-09-21f41ea6bd6efb…
2022-10-28 04:53 UTC2022-10N050748-002SYNERCID420MG/VIAL;180MG/VIALINJECTABLE / INTRAVENOUS2000-08-24f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N050748-001SYNERCID350MG/VIAL;150MG/VIALINJECTABLE / INTRAVENOUSRLD, RS1999-09-21e64feba35796…
2022-09-29 23:25 UTC2022-09N050748-002SYNERCID420MG/VIAL;180MG/VIALINJECTABLE / INTRAVENOUS2000-08-24e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N050748-001SYNERCID350MG/VIAL;150MG/VIALINJECTABLE / INTRAVENOUSRLD, RS1999-09-21cb3db0bc1861…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N050748-002SYNERCID420MG/VIAL;180MG/VIALINJECTABLE / INTRAVENOUS2000-08-24cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N050748-001SYNERCID350MG/VIAL;150MG/VIALINJECTABLE / INTRAVENOUSRLD1999-09-21a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N050748-002SYNERCID420MG/VIAL;180MG/VIALINJECTABLE / INTRAVENOUS2000-08-24a50c72e98297…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 5 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
61570-260Synercidquinupristin and dalfopristinPfizer Laboratories Div Pfizer IncNDACurrent
61570-260Synercidquinupristin and dalfopristinPfizer Laboratories Div Pfizer IncNDACurrent
61570-260Synercidquinupristin and dalfopristinPfizer Laboratories Div Pfizer IncNDACurrent
61570-260Synercidquinupristin and dalfopristinPfizer Laboratories Div Pfizer IncNDACurrent
61570-260Synercidquinupristin and dalfopristinPfizer Laboratories Div Pfizer IncNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
48777SUPPL2017-06-20
48754SUPPL2017-06-19
39240SUPPL2012-01-25
30434SUPPL2012-01-18
30433SUPPL2010-11-22
8169SUPPL2010-11-22
39239SUPPL2010-11-17
18166SUPPL2010-11-17
8168SUPPL2008-06-20
18165SUPPL2008-06-19
22215ORIG2001-07-18
30432ORIG1999-09-21
18164ORIG1999-09-21